Medication Guide App

Novolog Side Effects

Generic Name: insulin aspart

Note: This page contains side effects data for the generic drug insulin aspart. It is possible that some of the dosage forms included below may not apply to the brand name Novolog.

It is possible that some side effects of Novolog may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to insulin aspart: subcutaneous solution

As well as its needed effects, insulin aspart (the active ingredient contained in Novolog) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking insulin aspart, check with your doctor immediately:

More common
  • Anxious feeling
  • behavior change similar to being drunk
  • blurred vision
  • cold sweats
  • confusion
  • convulsions (seizures)
  • depression
  • difficulty with thinking
  • dizziness or lightheadedness
  • drowsiness
  • excessive hunger
  • fast heartbeat
  • headache
  • irritability or abnormal behavior
  • nightmares
  • restless sleep
  • shakiness
  • slurred speech
  • tingling in the hands, feet, lips, or tongue
  • unconsciousness
Less common or rare
  • Depression of the skin at the place of injection
  • dryness of the mouth
  • fast or weak pulse
  • feeling of pressure, itching, redness, soreness, stinging, swelling, or tingling at the place of injection
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • mood or mental changes
  • muscle cramps or pain
  • nausea or vomiting
  • shortness of breath
  • skin rash or itching over the whole body
  • sweating
  • thickening of the skin at the place of injection
  • unusual tiredness or weakness
  • wheezing

For Healthcare Professionals

Applies to insulin aspart: subcutaneous solution


Other cardiovascular risk factors that are accentuated in persons with carbohydrate intolerance and hypertension include abnormalities in platelet function, clotting factors, the fibrinolytic system, and dyslipidemia. The relationship between diabetes, insulin, and these disorders is currently under investigation.

Insulin may contribute to the pathogenesis of hypertension by stimulating the sympathetic nervous system, promoting renal sodium retention, and/or stimulating vascular smooth muscle hypertrophy. It may induce dyslipidemia by promoting hepatic synthesis of very low density lipoproteins (VLDLs).

Insulin may stimulate heart rate in the absence of hypoglycemia.[Ref]

Cardiovascular side effects have included hyperinsulinemia. Given the high frequency of both microvascular and macrovascular diseases in patients with diabetes and hyperinsulinemia, some experts are evaluating insulin as a possible atherogenic agent. Controversy and continued study surround the role of hyperinsulinemia as the precursor of hypertension.[Ref]


Dermatologic side effects of insulin have included lipohypertrophy (insulin is lipogenic) and lipoatrophy (probably immunologically-mediated). The incidence of lipoatrophy has been markedly decreased with the use of purer forms of pork insulin or biosynthetic human insulin and when injection sites were alternated. Without proper hygiene, subcutaneous insulin injections has been complicated by infection.[Ref]


Permanent neuropsychological impairment has been associated with recurrent episodes of severe hypoglycemia.

In one retrospective study of 600 randomly selected patients with insulin-treated diabetes mellitus, the only reliable predictors of severe hypoglycemia were a history of hypoglycemia, a history of hypoglycemia-related injury or convulsion, and the duration of insulin therapy. Those with a history of hypoglycemia had been treated with insulin for 17.4 years, which was significantly longer than the 14.3 years in the insulin-treated patients without a history of hypoglycemia.

Human insulin does not appear to be associated with hypoglycemic episodes more often than animal insulin. Caution is recommended when switching from animal (either bovine or pork) to purified porcine insulin or biosynthetic human insulin, however, because of increased potency or bioavailability.[Ref]

Endocrine side effects have included hypoglycemia, which has been the most common and serious side effect of insulin, occurring in approximately 16% of type 1 and 10% of type II diabetic patients (the incidence varies greatly depending on the populations studied, types of insulin therapy, etc). Although there are counterregulatory endocrinologic responses to hypoglycemia, some responses have been decreased, inefficient, or absent in some patients. Severe hypoglycemia has usually presented first as confusion, sweating, or tachycardia, and has resulted in coma, seizures, cardiac arrhythmias, neurological deficits, and death. Blood or urine glucose monitoring is recommended in patients who are at risk of hypoglycemia or who do not recognize the signs and symptoms of hypoglycemia. The risk for developing hypoglycemia has been higher in patients receiving intensive or continuous infusion insulin therapy. The association between insulin and dyslipidemia is currently being evaluated.[Ref]


Gastrointestinal side effects have been reported rarely. GI distress has tended to resolve after dose reduction.[Ref]


General side effects have included weight gain, sometimes presenting as edema associated with abrupt restoration of glucose control in a patient whose control was previously poor. Weight gain may have been due to more efficient use of calories during insulin therapy, suggesting additional benefits of dietary and exercise modifications. Patients on intensive insulin therapy have been more likely to experience weight gain.[Ref]

Intensive insulin therapy causes an increase in body fat as a result of the elimination of glycosuria and reduction in 24-hour energy expenditure. The reduction in 24-h energy expenditure is the result of an insulin-associated decrease in triglyceride/free fatty acid cycling and nonoxidative glucose and protein metabolism.[Ref]


Hematologic side effects have included an increase in the concentration of von Willebrand factor due to insulin-induced hypoglycemia. Increased von Willebrand factor, combined with hypoglycemia-associated decreased plasma volume and increased plasma viscosity, may have predisposed patients to reduced peripheral perfusion or embolic phenomenon. A single case of insulin-induced hemolytic anemia has been reported.[Ref]

The effects of insulin-induced hypoglycemia on hemostasis may explain some of the clinical observations of embolic phenomenon during treatment of diabetic ketoacidosis.

Limited data show that diabetics have a significantly lower basal concentration of tissue plasminogen activator.[Ref]


A diabetic patient with true allergy to insulin can undergo desensitization. Desensitization kits and protocols are available from some insulin manufacturers.[Ref]

Hypersensitivity side effects have included both local and systemic reactions. These reactions are becoming rare (less than 1% of patients) due to the use of purer forms of pork insulin or biosynthetic human insulin. Local reactions have presented as erythema, swelling, heat, or subcutaneous nodules. They usually occurred within the first two weeks of therapy, then disappeared. True allergy to insulin has been rare, and sensitization was usually associated with specific animal proteins in bovine and less pure forms of porcine insulins. Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with any insulin product, including insulin aspart. Anaphylactic reactions with insulin aspart have been reported post- approval. Generalized allergy to insulin may also cause whole body rash (including pruritus), dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.[Ref]


Immunologic side effects have included the formation of anti-insulin antibodies, particularly when animal insulin formulations were used. The presence of these antibodies caused the elimination half-life of insulin to increase.

Increases in levels of anti-insulin antibodies that react with both human insulin and insulin aspart (the active ingredient contained in Novolog) have been observed in patients treated with insulin aspart. These antibodies do not appear to cause deterioration in HbA1c or to necessitate increases in insulin dose.[Ref]

Immunologic analysis of anaphylaxis to some insulin preparations in some cases has revealed markedly elevated serum levels of lgE and lgG to protamine, but not to regular insulin.[Ref]


Rare cases of hypophosphatemia have been associated with the use of glucose, insulin, and potassium infusions during the treatment of myocardial infarction.[Ref]

Metabolic side effects have included reports of hypokalemia and hypomagnesemia, particularly in patients treated for diabetic ketoacidosis (DKA). Insulin increases the intracellular transport of phosphate, which often results in hypophosphatemia during treatment of DKA.[Ref]


Ocular side effects have included reports bilateral presyopia (blurry vision) during the beginning of therapy. This was thought to be due to changes in the osmotic equilibrium between the lens and the ocular fluids, and was usually self-limited.[Ref]


Renal effects have included reports of significantly decreased renal plasma flow, glomerular filtration rate, and significantly increased urinary albumin excretion rate from insulin-induced hypoglycemia. These changes were usually reversible upon resolution of hypoglycemia.[Ref]

Hypoglycemia is associated with increased plasma dopamine, epinephrine, and plasma renin activity. Acute changes in renal function during insulin-induced hypoglycemia, therefore, may result from direct stimulation of the efferent sympathetic nerves to the kidney and hormonal counterregulatory mechanisms.[Ref]


1. Savage PJ, Soad MF "Insulin and atherosclerosis: villain bystander?" Br Heart J 69 (1993): 473-5

2. Koh H, Nambu S, Tsushima M, et al "The effects of insulin on the cardiovascular system in patients with coronary heart disease." Arzneimittelforschung 34 (1984): 185-90

3. Collier A, Matthews DM, Young RJ, Clarke BF "Transient atrial fibrillation precipitated by hypoglycaemia: two case reports." Postgrad Med J 63 (1987): 895-7

4. Bressler R, Galloway JA "The insulins." Ration Drug Ther 5 (1971): 1-6

5. Stern MP "Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?" Ann Intern Med 124(1 Pt 2) (1996): 110-6

6. Siani A, Strazzullo P, Giorgione N, et al "Insulin-induced increase in heart rate and its prevention by propranolol." Eur J Clin Pharmacol 38 (1990): 393-5

7. Swislocki A "Insulin resistance and hypertension." Am J Med Sci 300 (1990): 104-15

8. Patrick AW, Campbell IW "Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes." Diabetic Med 7 (1990): 349-54

9. Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980): 69-71

10. Hilsted J, Bonde-Petersen F, Norgaard M-B, et al "Haemodynamic changes in insulin-induced hypoglycaemia in normal man." Diabetologia 26 (1984): 328-32

11. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K "Hyperinsulinemia factors in the pathogenesis of hypertension and atherosclerosis." Am J Hypertens 6 (1993): s260-70

12. Wingard DL, Barrettconnor EL, Ferrara A "Is insulin really a heart disease risk factor?" Diabetes Care 18 (1995): 1299-304

13. Jarrett RJ "Insulin and atheroma." Lancet 05/30/87 (1987): 1272

14. Bohrer H, Fleischer F, Krier C "Hyperkalemic cardiac arrest after cardiac surgery following high-dose glucose-insulin-potassium infusion for inotropic support." Anesthesiology 69 (1988): 949-53

15. Vettor R, Mazzonetto P, Macor C, Scandellari C, Federspil G "Effect of endogenous organic hyperinsulinaemia on blood pressure and serum triglycerides." Eur J Clin Invest 24 (1994): 350-4

16. Stout RW "Overview of the association between insulin and atherosclerosis." Metabolism 34 (1985): 7-12

17. Genuth S "Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus." Ann Intern Med 124(1 Pt 2) (1966): 104-9

18. Standl E "Hyperinsulinemia and atherosclerosis." Clin Invest Med 18 (1995): 261-6

19. Mantle JA, Rogers WJ, Smith LR, et al "Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction: results from a randomized clinical trial." Am Heart J 102 (1981): 313-24

20. Jarrett RJ "Is insulin atherogenic?" Diabetologia 31 (1988): 71-5

21. Scoppola A, Testa G, Frontoni S, Maddaloni E, Gambardella S, Menzinger G, Lala A "Effects of insulin on cholesterol synthesis in type II diabetes patients." Diabetes Care 18 (1995): 1362-9

22. Mann SJ, Krakoff LR "Hypertensive crisis caused by hypoglycemia and propranolol." Arch Intern Med 144 (1984): 2427-8

23. Wieczorek I, Pell AC, McIver B, MacGregor IR, Ludlam CA, Frier BM "Coagulation and fibrinolytic systems in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia." Clin Sci (Colch) 84 (1993): 79-86

24. Brown RT, Polinsky RJ, Baucom CE "Euglycemic insulin-induced hypotension in autonomic failure." Clin Neuropharmacol 12 (1989): 227-31

25. Skyler JS "Human insulin after 10 years." Diabetes Care 16 Suppl 3 (1993): 1-3

26. Tenkanen L, Manttari M, Manninen V "Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the helsinki heart study." Circulation 92 (1995): 1779-85

27. Slater EE "Insulin resistance and hypertension." Hypertension 18 (1991): I108-14

28. Shinozaki K, Suzuki M, Ikebuchi M, Takaki H, Hara Y, Tsushima M, Harano Y "Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina." Circulation 92 (1995): 1749-57

29. Evans DJ, Pritchard-Jones K, Trotman-Dickenson B "Insulin oedema." Postgrad Med J 62 (1986): 665-8

30. Takata S, Yamamoto M, Yagi S, et al "Peripheral circulatory effects of insulin in diabetes." Angiology Feb (1985): 110-5

31. MacDonald MJ "Conventional and human insulin: complications of insulin therapy in children." Prim Care 10 (1983): 691-706

32. Wheatley T, Edwards OM "Insulin oedema and its clinical significance: metabolic studies in three cases." Diabetic Med 2 (1985): 400-4

33. Pladziewicz DS, Nesto RW "Hypoglycemia-induced silent myocardial ischemia." Am J Cardiol 63 (1989): 1531-2

34. Reeves WG, Allen BR, Tattersall RB "Insulin-induced lipoatrophy: evidence for an immune pathogenesis." Br Med J 06/21/80 (1980): 1500-3

35. Fleming MG, Simon SI "Cutaneous insulin reaction resembling acanthosis nigricans." Arch Dermatol 122 (1986): 1054-6

36. Chin RL, Martinez R, Garmel G "Gas gangrene from subcutaneous insulin administration." Am J Emerg Med 11 (1993): 622-5

37. Pietri A, Raskin P "Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy." Diabetes Care 4 (1981): 624-6

38. Brogden RN, Heel RC "Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use." Drugs 34 (1987): 350-71

39. Valenta LJ, Elias AN "Insulin-induced lipodystrophy in diabetic patients resolved by treatment with human insulin." Ann Intern Med 102 (1985): 790-1

40. Goldman JM, Wheeler MF "Lipodystrophy from recombinant DNA human insulin." Am J Med 83 (1987): 195-6

41. Berman BA, Ross RN "Conversations on allergy and immunology: insulin hypersensitivity." Cutis 32 (1983): 320,28,30,32

42. Elte JW, van der Schroeff JG, van Leeuwen AW, Radder JK "Sclerosing granuloma after short-term administration of depot-insulin hoechst." Klin Wochenschr 60 (1982): 1461-4

43. Schernthaner G "Immunogenicity and allergenic potential of animal and human insulins." Diabetes Care 16 Suppl 3 (1993): 155-65

44. Fish HR, Chernow B, O'Brian JT "Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycemia: a review." Metabolism 35 (1986): 763-80

45. Arnqvist HJ, Halban PA, Mathiesen UL, Zahnd G, von Schenck H "Hypoglycaemia caused by atypical insulin antibodies in a patient with benign monoclonal gammopathy." J Intern Med 234 (1993): 421-7

46. Moses RG, Hubert PA, Lewis-Driver DJ "Severe hypoglycaemia: a one-year prospective survey in wollongong." Med J Aust 142 (1985): 294-6

47. Tattersall RB, Gill GV "Unexplained deaths of type 1 diabetic patients." Diabetic Med 8 (1991): 49-58

48. Johansen K, Ellegaard S, Wex S "Detection of nocturnal hypoglycemia in insulin-treated diabetics by a skin temperature-skin conductance meter." Acta Med Scand 220 (1986): 213-7

49. Reichard P, Britz A, Rosenqvist U "Intensified conventional insulin treatment and neuropsychological impairment." Br Med J 303 (1991): 1439-42

50. von Kriegstein E "Hypoglycaemia with human and porcine insulins." BMJ 306 (1993): 720

51. Bernstein RK "The somogyi phenomenon." Arch Intern Med 145 (1985): 575

52. Frier BM, Corrall RJ, Davidson NM, et al "Peripheral blood cell changes in response to acute hypoglycaemia in man." Eur J Clin Invest 13 (1983): 33-9

53. Ziegler D, Hubinger A, Gries FA "Changes in brainstem auditory evoked potentials during insulin-induced hypoglycaemia in type 1 diabetic patients." Diabetic Med 8 (1991): 805-11

54. Wredling R, Levander S, Adamson U, Lins PE "Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man." Diabetologia 33 (1990): 152-7

55. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM "Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin." Diabet Med 10 (1993): 231-7

56. Tzamaloukas AH, Avasthi PS "Hypoglycemia during hemodialysis in diabetics treated with insulin." Nephron 61 (1992): 470-1

57. Steel JM, Masterton G, Patrick AW, McGuire R "Hyperventilation or hypoglycaemia?" Diabetic Med 6 (1989): 820-1

58. Kiser D "The somogyi effect." Am J Nurs Feb (1980): 236-8

59. Garre M, Boles JM, Garo B, Mabin D "Cerebral oedema in diabetic ketoacidosis: do we use too much insulin?" Lancet 1 (1986): 220

60. Karam J, Brink S, Clements R, et al "Evaluation of efficacy and safety of human insulin (novo) in the treatment of insulin-dependent diabetes mellitus: a double-blind, multicenter clinical trial." Diabetes Care 6 (1983): 56-60

61. Langan SJ, Deary IJ, Hepburn DA, Frier BM "Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus." Diabetologia 34 (1991): 337-44

62. MacLeod KM, Hepburn DA, Frier BM "Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients." Diabet Med 10 (1993): 238-45

63. Kalimo H, Olsson Y "Effects of severe hypoglycemia on the human brain." Acta Neurol Scand 62 (1980): 345-56

64. Borch-Johnsen K, Helweg-Larsen K "Sudden death and human insulin: is there a link?" Diabet Med 10 (1993): 255-9

65. Brodows RG, Williams C, Amatruda JM "Treatment of insulin reactions in diabetics." JAMA 252 (1984): 3378-81

66. Bhatia V, Wolfsdorf JI "Severe hypoglycemia in youth with insulin-dependent diabetes mellitus: frequency and causative factors." Pediatrics 88 (1991): 1187-93

67. Kerr D, Reza M, Smith N, Leatherdale BA "Importance of insulin in subjective, cognitive, and hormonal responses to hypoglycemia in patients with IDDM." Diabetes 40 (1991): 1057-62

68. Krahn DD, Mackenzie TB "Organic personality syndrome caused by insulin-related nocturnal hypoglycemia." Psychosomatics 25 (1984): 711-2

69. Orchard TJ, Maser RE, Becker DJ, et al "Human insulin use and hypoglycaemia: insights from the pittsburgh epidemiology of diabetes complications study." Diabetic Med 8 (1991): 469-74

70. Wolf JP, Massol J, Nguyen NU, Berthelay S "Arginine vasopressin response to insulin-induced hypoglycemia in insulin-dependent diabetics with asymptomatic hypoglycemia." Horm Metab Res 22 (1990): 232-6

71. Egger M, Smith GD, Teuscher A "Hypoglycaemia with human and porcine insulins." BMJ 306 (1993): 719-20

72. Stangenberg M, Persson B, Stange L, Carlstrom K "Insulin-induced hypoglycemia in pregnant diabetics." Acta Obstet Gynecol Scand 62 (1983): 249-52

73. Caprio S, Amiel S, Tamborlane WV, et al "Defective free-fatty acid and oxidative glucose metabolism in IDDM during hypoglycemia." Diabetes 39 (1990): 134-41

74. Block MB, Rubenstein AH "Spontaneous hypoglycemia in diabetic patients with renal insufficiency." JAMA 213 (1970): 1863-6

75. Yoo J, Peter S, Kleinfeld M "Transient hypoglycemic hemiparesis in an elderly patient." J Am Geriatr Soc 34 (1986): 479-81

76. Urdl W, Desoye G, Schmon B, et al "Interactions between insulin and insulin-like growth factor I in the pathogenesis of polycystic ovarian disease." Ann N Y Acad Sci 626 (1991): 177-83

77. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA "Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old." Diabetes Res Clin Pract 28 (1995): 173-7

78. Berger W, Honegger B, Keller U, Jaeggi E "Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus." Lancet 05/13/89 (1989): 1041-4

79. Lingenfelser T, Renn W, Plonz C, et al "Catecholamine response during human and pork insulin-induced hypoglycemia in IDDM patients." Diabetes Care 15 (1992): 261-4

80. Daniel DG, Rabin PL "Disguises of delirium." South Med J 78 (1985): 666-72

81. Shimada R, Nakashima T, Nunoi K, et al "Arrhythmia during insulin-induced hypoglycemia in a diabetic patient." Arch Intern Med 144 (1984): 1068-9

82. Walker JD, Viberti G "Recurrent nocturnal hypoglycemia in an insulin-dependent diabetic patient receiving a small daily dose of insulin." Am J Med 88 (1990): 537-9

83. Lingenfelser T, Renn W, Sommerwerck U, Jung MF, Buettner UW, Zaiser-Kaschel H, Kaschel R, Eggstein M, Jakober B "Compromised hormonal counterregulation neurophysiological function after recurrent short-term episodes of insulin-induced hypoglycemia in IDDM patients." Diabetes 42 (1993): 610-8

84. Boden G, Reichard GA, Hoeldtke RD, et al "Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones." N Engl J Med 305 (1981): 1200-5

85. Teuscher A, Reinli K "Severe hypoglycaemia in Diabetes Control and Complications Trial." Lancet 343 (1994): 1097-8

86. Kidson W "The Somogyi effect. Has it ever existed and what harm has it caused?" Med J Aust 159 (1993): 480-2

87. Riddle MC "Relief of gastrointestinal symptoms by correcting insulin excess." Diabetes Care 4 (1981): 296-8

88. Santiago JV "Intensive management of insulin dependent diabetes: risks, benefits, and unanswered questions." J Clin Endocrinol Metab 75 (1992): 977-82

89. Carlson MG, Campbell PJ "Intensive insulin therapy and weight gain in IDDM." Diabetes 42 (1993): 1700-7

90. Fisher BM, Quin JD, Rumley A, et al "Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects." Clin Sci 80 (1991): 525-31

91. Yamreudeewong W, Cavell RM, Henann NE "Possible hemolytic anemia associated with human insulin therapy." DICP 24 (1990): 887

92. Fisher BM, Smith JG, McCruden DC, Frier BM "Responses of peripheral blood cells and lymphocyte subpopulations to insulin-induced hypoglycaemia in human insulin-dependent (type 1) diabetes." Eur J Clin Invest 17 (1987): 208-13

93. Chideckel EW, Mullin CJ, Michael BE "Cimetidine in insulin allergy." Diabetes Care 4 (1981): 503-4

94. Naparstek Y, Ben-Chetrit E, Okon E, Estrov Z, Eliakim M "Angioimmunoblastic lymphadenopathy in a patient with allergy to insulin: a case report." Cancer 47 (1981): 545-7

95. Wurzburger MI, Prelevic GM, Despotovic N, et al "Delayed-type allergy against various insulin preparations including human semisynthetic insulin." Ann Allergy 59 (1987): 44-7

96. Carveth-Johnson AO, Mylvaganam K, Child DF "Generalised allergic reaction with synthetic human insulin." Lancet 12/04/82 (1982): 1287

97. Small P, Lerman S "Human insulin allergy." Ann Allergy 53 (1984): 39-41

98. Stewart WJ, McSweeney SM, Kellett MA, et al "Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization." Circulation 70 (1984): 788-92

99. Simmonds JP, Russell GI, Cowley AJ, et al "Generalised allergy to porcine and bovine monocomponent insulins." Br Med J 08/02/80 (1980): 355-6

100. Burcelin RG, Eddouks M, Beylot M, Normand S, Boitard C, Feutren G, Landais P, Riou JP, Girard JR, Bach JF, et al "Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients." Diabetes Care 16 (1993): 881-8

101. Lyngsoe J, Vestermark S "The efficacy and safety of human insulin (novo) in insulin-dependent diabetic patients." Diabetes Care 6 (1983): 53-5

102. Goldman JM, Brynildsen HC "Generalised allergy to porcine and bovine monocomponent insulins." Br Med J 281 (1980): 1494

103. Thompson DM, Ronco JJ "Prolonged desensitization required for treatment of generalized allergy to human insulin." Diabetes Care 16 (1993): 957-8

104. Ross JM, Murali MR, DeLara TC, Cheron RG "Anaphylaxis and immunologic insulin resistance in a diabetic woman with ketoacidosis." Diabetes Care 7 (1984): 276-9

105. Silverstone P "Generalised allergic reaction to human insulin." Br Med J 292 (1986): 933-4

106. Altman JJ, Pehuet M, Slama G, Tchobroutsky C "Three cases of allergic reaction to human insulin." Lancet 2 (1983): 524

107. Gossain VV, Rovner DR, Mohan K "Systemic allergy to human (recombinant DNA) insulin." Ann Allergy 55 (1985): 116-8

108. Diem P, Spengler H, De Weck AL "Lymphocyte transformation by insulin and insulin-zinc suspensions." Clin Exp Immunol 50 (1982): 155-62

109. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P "Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin." J Allergy Clin Immunol 93 (1994): 117-25

110. Yasuda H, Nagata M, Moriyama H, et al. "Human insulin analog insulin aspart does not cause insulin allergy." Diabetes Care 24 (2001): 2008-9

111. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,

112. Jovanovic-Peterson L, Sparks S, Palmer JP, Peterson CM "Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle- injected insulin in gestational diabetic women." Diabetes Care 16 (1993): 1479-84

113. Micic D, Brkic S, Kendereski A, Popovic V, Zoric S, Nikolic JA, Igrutinovic L, Ivanoska D, Manojlovic D, Micic J "Immunological resistance to human biosynthetic insulin--effects of immunosuppression and plasmapheresis." Diabetes Res Clin Pract 19 (1993): 83-9

114. Kahn CR, Mann D, Rosenthal AS, et al "The immune response to insulin in man: interaction of HLA alloantigens and the development of the immune response." Diabetes 31 (1982): 716-23

115. Marwick TH, Woodhouse SP "Severe hypophosphataemia induced by glucose-insulin-potassium therapy. A case report and proposal for altered protocol." Int J Cardiol 18 (1988): 327-30

116. Frier BM, Hepburn DA, Fisher BM, Barrie T "Fall in intraocular pressure during acute hypoglycaemia in patients with insulin dependent diabetes." Br Med J 294 (1987): 610-1

117. Sjolie AK "Ocular complications in insulin treated diabetes mellitus." Acta Ophthalmol (Copenh) S172 (1985): 1-77

118. Christensen CK, Christiansen JS, Christensen T, et al "The effect of six months continuous subcutaneous insulin infusion on kidney function and size in insulin-dependent diabetics." Diabetic Med 3 (1986): 29-32

119. Patrick AW, Hepburn DA, Swainson CP, Frier BM "Changes in renal function during acute insulin-induced hypoglycaemia in patients with type 1 diabetes." Diabetic Med 9 (1992): 150-5

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.